Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
31 March-01 April, 2025
Plastics Recycling EUPlastics Recycling EU
Not Confirmed
Not Confirmed
01-02 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
31 March-01 April, 2025
Plastics Recycling EUPlastics Recycling EU
Industry Trade Show
Not Confirmed
01-02 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
10 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/mediar-therapeutics-enters-into-global-licensing-agreement-with-lilly-to-advance-first-in-class-wisp1-antibody-for-the-treatment-of-idiopathic-pulmonary-fibrosis-ipf-302347905.html
07 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/mediar-therapeutics-initiates-second-clinical-program-in-portfolio-of-novel-first-in-class-antibodies-designed-to-halt-fibrosis-302215886.html
07 May 2024
// PHARMABIZ
25 Oct 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/mediar-therapeutics-announces-clinical-candidates-for-lead-fibrosis-programs-strategic-collaborations-and-key-leadership-addition-301966378.html
25 Oct 2023
// Max Bayer FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/mediar-gets-spark-pfizers-ignite-program-lead-programs-progress
15 Mar 2023
// James Waldron FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/armed-105m-and-big-pharma-backing-mediar-takes-aim-fibrotic-mediators
Details:
Under the licensing agreement, Lilly will have the right to lead all further clinical development and commercialization of the MTX-463 for treating idiopathic pulmonary fibrosis.
Lead Product(s): MTX-463
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: MTX-463
Study Phase: Phase IProduct Type: Antibody
Sponsor: Eli Lilly
Deal Size: $786.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 10, 2025
Lead Product(s) : MTX-463
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : $786.0 million
Deal Type : Licensing Agreement
Mediar Therapeutics Signs Global License with Lilly for WISP1 Antibody in IPF
Details : Under the licensing agreement, Lilly will have the right to lead all further clinical development and commercialization of the MTX-463 for treating idiopathic pulmonary fibrosis.
Product Name : MTX-463
Product Type : Antibody
Upfront Cash : Undisclosed
January 10, 2025
Details:
MTX-474 is a first-in-class human IgG1 antibody designed to neutralize the EphrinB2 signaling that causes the onset and progression of fibrosis.
Lead Product(s): MTX-474
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: MTX-474
Study Phase: Phase IProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 08, 2024
Lead Product(s) : MTX-474
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mediar Therapeutics Starts Second Program of Antibodies to Halt Fibrosis
Details : MTX-474 is a first-in-class human IgG1 antibody designed to neutralize the EphrinB2 signaling that causes the onset and progression of fibrosis.
Product Name : MTX-474
Product Type : Antibody
Upfront Cash : Inapplicable
July 08, 2024
Details:
MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). It is being evaluated for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): MTX-463
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: MTX-463
Study Phase: Phase IProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 05, 2024
Lead Product(s) : MTX-463
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mediar Advances Fibrosis To Clinic With First Cohort Dosing In Phase 1 Of MTX-463
Details : MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). It is being evaluated for the treatment of idiopathic pulmonary fibrosis.
Product Name : MTX-463
Product Type : Antibody
Upfront Cash : Inapplicable
July 05, 2024
Details:
The series A financing will support advancement of the company’s portfolio of first-in-class antibody treatments, which offer unique potential to address fibrosis at varying stages of the disease, with two programs advancing into human studies in 2024.
Lead Product(s): Undisclosed
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Antibody
Sponsor: Novartis Venture Fund
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Novartis Venture Fund
Deal Size : $105.0 million
Deal Type : Financing
Details : The series A financing will support advancement of the company’s portfolio of first-in-class antibody treatments, which offer unique potential to address fibrosis at varying stages of the disease, with two programs advancing into human studies in 2024.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 15, 2023
Details:
Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.
Lead Product(s): Undisclosed
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Antibody
Sponsor: Distributed Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Distributed Bio
Deal Size : Undisclosed
Deal Type : Partnership
Distributed Bio Partners With Mediar Therapeutics, Inc.
Details : Under the terms of this partnership, Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 06, 2020
ABOUT THIS PAGE